|
Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Genentech; Gilead Sciences; Medivation; Taiho Pharmaceutical |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Consulting or Advisory Role - Amgen; Sirtex Medical; Taiho Pharmaceutical |
Speakers' Bureau - Genentech |
Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Amgen; Genentech; Lilly |
|
|
Consulting or Advisory Role - Bayer; Sandoz |
Speakers' Bureau - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz |